EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, is now recruiting
Cure Parkinson’s is excited to announce that the first multi-arm multi-stage clinical trial platform for Parkinson’s in the UK – EJS ACT-PD – is underway, with recruitment now open to people with Parkinson’s. The Edmond J. Safra Accelerating Clinical Trials for Parkinson’s Disease (EJS ACT-PD)...
Learn more
A review of our 2023 preclinical projects
In 2023, Cure Parkinson’s has funded five new preclinical projects. These preclinical projects address a wide range of ‘targets’ to understand which drugs and which targets should be further tested in a clinical trial.
A new potential biomarker for Parkinson’s
Researchers at Duke University have recently presented data on a new potential biomarker for Parkinson’s.
Our first pipeline project of research
Our first project from our Research Pipeline Acceleration Programme is now underway. Professor Michael Schwarzchild is investigating evidence needed to determine if three iLCT-evaluated compounds are ready to progress into clinical trials for people with Parkinson’s.
2023 Tom Isaacs Award honours Dr Natasha Fothergill-Misbah
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Natasha Fothergill-Misbah, Research Associate at Newcastle University, as the winner of the 2023 Tom Isaacs Award. The award was presented to Natasha in Newcastle, as part of the annual Grand Challenges in Parkinson’s…
New research exploring ethnic diversity in Parkinson’s
A recent study from the Global Parkinson’s Genetic Program found a novel genetic risk factor for Parkinson’s in people of African ancestry. This finding once again brings to light the ongoing need for improving diversity in Parkinson’s research.